Last updated 10 days ago

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

250 patients around the world

Available in United States, Brazil

Genentech, Inc.

2Research sites

250Patients around the world

This study is for people with

Solid tumors

Requirements for the patient

From 18 Years

All Gender

Medical requirements

Sites

Hospital de Clínicas de Porto Alegre - HCPA/UFRGS

Recruiting

Rua Ramiro Barcelos, 2350, Av. Protásio Alves, 211 - Santa Cecília, Porto Alegre - RS, 90035-903

Instituto do Câncer do Estado de São Paulo "Octavio Frias de Oliveira" - ICESP

Recruiting

Av. Dr. Arnaldo, 251 - Consolação, São Paulo - SP, 01255-090, Brazil

SponsorGenentech, Inc.

Study typeInterventional

Conditions

Solid tumors

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT04250155